Print Page  |  Close Window

Investor Overview

NASDAQ: XBIT0.310.64Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
DateTitle 
03/05/19Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without AntibioticsPrinter Friendly Version
03/01/19Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual MeetingPrinter Friendly Version
01/29/19Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual MeetingPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »